Synairgen reported a FY 2021 adjusted net loss of £48.2m (FC est. -£46.7m), the delta due to higher-than-expected R&D (c.£4.9m), which was partially offset by a higher R&D tax credit. Period-end cash was £33.8m (FC est. £37.0m). SPRINTER results, presented at the American Thoracic Society on 16 May, identify a responder group of higher risk patients and provide a strong clinical rationale to investigate SNG001 in a trial evaluating progression and/or mortality in such patients. Synairgen is focu ....
25 May 2022
Synairgen - FY 2021 – focused on SNG001 inclusion in platform trial
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Synairgen - FY 2021 – focused on SNG001 inclusion in platform trial
Synairgen plc (SNG:LON) | 6.6 0 2.3% | Mkt Cap: 13.3m
- Published:
25 May 2022 -
Author:
Mark Brewer | Cavendish Research -
Pages:
14
Synairgen reported a FY 2021 adjusted net loss of £48.2m (FC est. -£46.7m), the delta due to higher-than-expected R&D (c.£4.9m), which was partially offset by a higher R&D tax credit. Period-end cash was £33.8m (FC est. £37.0m). SPRINTER results, presented at the American Thoracic Society on 16 May, identify a responder group of higher risk patients and provide a strong clinical rationale to investigate SNG001 in a trial evaluating progression and/or mortality in such patients. Synairgen is focu ....